Search
forLearn
5 / 801 resultslearn Biotinyl-GHK
learn Vascular Endothelial Growth Factor
learn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
Research
5 / 139 results
research TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
research The influence of interferon on healthy and diseased skin
Type I interferons play a key role in the development of various skin diseases.
research New small molecules in dermatology: for the autoimmunity, inflammation and beyond
New small molecule drugs show promise in treating complex skin diseases but need more safety research.
research Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
Gray hair can potentially be reversed, leading to new treatments.
research Keratin 17 modulates hair follicle cycling in a TNFα-dependent fashion
Keratin 17 is crucial for normal hair growth by regulating hair cycle transitions with TNFα.
Community Join
5 / 1000+ resultscommunity IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).